This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martín, V. Articles by Rodriguez, C. Search for Related Content PubMed PubMed Citation Articles by Martín, V. Articles by Rodriguez, C.

Intracellular Signaling Pathways Involved in the Cell Growth Inhibition of Glioma Cells by Melatonin

¹ Departamento de Morfología y Biología Celular and ² Instituto Universitario de Oncología del Principado de Asturias, Facultad de Medicina de la Universidad de Oviedo, Oviedo, Spain

Requests for reprints: Carmen Rodriguez, Departamento de Morfología y Biología Celular, Facultad de Medicina de la Universidad de Oviedo, Calle Julian Claveria, 33006 Oviedo, Spain. Phone: 34-98-510-3057; Fax: 34-98-510-3618; E-mail: carro{at}uniovi.es.

Melatonin is an indolamine mostly produced in the pineal gland, soluble in water, and highly lipophilic, which allows it to readily cross the blood-brain barrier. Melatonin possesses antioxidant properties and its long-term administration in rodents has not been found to cause noteworthy side effects. In the present work, we found that millimolar concentrations of this indolamine reduced cell growth of C6 glioma cells by 70% after 72 hours of treatment, inhibiting cell progression from G₁ to S phase of the cell cycle. Intraperitoneal administration of 15 mg/kg body weight of melatonin to rats previously injected in the flank with C6 glioma cells reduces tumor growth by 50% 2 weeks after the implant. Inhibition of cell growth does not depend on melatonin membrane receptor activation whereas it seemingly relates to the reduction of intracellular basal free radical levels by 30%. Increase of basal redox state of the cells and constitutive activation of tyrosine kinase receptor [receptor tyrosine kinase (RTK)] pathways, including the extracellular signal–regulated kinase 1/2 (ERK1/2) and the Akt and protein kinase C (PKC) signaling pathways, contribute to the progression of the gliomas leading to the constitutive activation of the redox-dependent survival transcription factor nuclear factor B (NF-B). The antioxidant effect of melatonin in C6 cells is associated to inhibition of NF-B and Akt, but not of ERK1/2. The antiproliferative effect of the indolamine on these cells is partially abolished when coincubated with the PKC activator 12-O-tetradecanoylphorbol-13-acetate, thus indicating that the ability of melatonin to change cellular redox state may be inactivating the pathway RTK/PKC/Akt/NF-B. (Cancer Res 2006; 66(2): 1081-8)

This article has been cited by other articles:

				G. Filomeni, G. Cerchiaro, A. M. Da Costa Ferreira, A. De Martino, J. Z. Pedersen, G. Rotilio, and M. R. Ciriolo Pro-apoptotic Activity of Novel Isatin-Schiff Base Copper(II) Complexes Depends on Oxidative Stress Induction and Organelle-selective Damage J. Biol. Chem., April 20, 2007; 282(16): 12010 - 12021. [Abstract] [Full Text] [PDF]

				B. Jung and N. Ahmad Melatonin in cancer management: progress and promise. Cancer Res., October 15, 2006; 66(20): 9789 - 9793. [Abstract] [Full Text] [PDF]

				D. Wion, F. Berger, and N. Wion-Barbot Glioma, melatonin, and radiotherapy. Cancer Res., June 15, 2006; 66(12): 6457 - 6457. [Full Text] [PDF]